Table 1 Expression of KRT80 in NSCLC patients and its correlation with clinicopathological parameters.

From: Keratin 80 as a diagnostic biomarker with limited prognostic value in non-small cell lung cancer

Factors

Cases (n)

KRT80 expression

P value

Negative

Positive

    

0.000

Cancer

175

62(35.4%)

113(64.6%)

 

Non-cancerous

175

123(70.3%)

52(29.7%)

 

Area

   

0.000

Xuanwei

72

12(16.7%)

60(83.3%)

 

Non-Xuanwei

103

50(48.5%)

53(51.5%)

 

Gender

   

0.316

Male

107

41(38.3%)

66(61.7%)

 

Female

68

21(30.9%)

47(69.1%)

 

Age(y)

   

0.045

≤ 60

105

31(29.5%)

74(70.5%)

 

>60

70

31(44.3%)

39(55.7%)

 

Smoking history

   

0.710

No

104

38(36.5%)

66(63.5%)

 

Yes

71

24(33.8%)

47(66.2%)

 

Drinking history

   

0.497

No

143

49(34.3%)

94(65.7%)

 

Yes

32

13(40.6%)

19(59.4%)

 

Differentiation

   

0.759

Low

23

10(43.5%)

13(56.5%)

 

Moderately

92

33(35.9%)

59(64.1%)

 

High

20

7(35%)

13(65%)

 

Unknow

40

12(30%)

28(70%)

 

Pathological type

   

0.001

Squamous Carcinoma

44

25(56.8%)

19(43.2%)

 

Adenocarcinoma

131

37(28.2%)

94(71.8%)

 

pT stage

   

0.930

T1

94

33(35.1%)

61(64.9%)

 

T2

60

21(35.0%)

39(65.0%)

 

T3

17

6(35.3%)

11(64.7%)

 

T4

4

2(50.0%)

2(50.0%)

 

Lymph node metastasis(pN stage)

   

0.875

Negative

103

36(35.0%)

67(65.0%)

 

Positive

72

26(36.1%)

46(63.9%)

 

AJCC stage at diagnosis(pTNM)

   

0.863

I

86

32(37.2%)

54(62.8%)

 

II

34

12(35.3%)

22(64.7%)

 

III

55

18(32.7%)

37(67.3%)

 

Tumor size(AJCC 8)

   

0.238

≤3 cm

71

20(28.2%)

51(71.8%)

 

3 < d ≤ 5 cm

60

23(38.3%)

37(61.7%)

 

>5 cm

42

18(42.9%)

24(57.1%)

 
  1. *According to the χ2 test. NSCLC: Non-small cell lung cancer; pT, pathological tumor size; pN, pathological lymph node stage; AJCC, American Joint Committee on Cancer; TNM, Tumor‑Node‑Metastasis. Tumor size was evaluated according to the maximum diameter of the tumor.
Back to article page